A fourth dose of the Pfizer-BioNTech vaccine was insufficient to prevent infection with the omicron variant of Covid-19, according to preliminary data from a trial in Israel released Monday.
Two weeks after the start of the trial of 154 medical personnel at the Sheba Medical Center in Tel Aviv, researchers found the vaccine raised antibody levels.
Subscribe to our YouTube channel: [ Ссылка ]
Subscribe to our newest channel Quicktake Explained: [ Ссылка ]
Bloomberg Quicktake brings you live global news and original shows spanning business, technology, politics and culture. Make sense of the stories changing your business and your world.
To watch complete coverage on Bloomberg Quicktake 24/7, visit [ Ссылка ], or watch on Apple TV, Roku, Samsung Smart TV, Fire TV and Android TV on the Bloomberg app.
Have a story to tell? Fill out this survey for a chance to have it featured on Bloomberg Quicktake: [ Ссылка ]
Connect with us on…
YouTube: [ Ссылка ]
Breaking News on YouTube: [ Ссылка ]
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
![](https://s2.save4k.ru/pic/Ebz6zN9XAVc/mqdefault.jpg)